HR Execs on the Move

Aphria Incorporated

www.aphriainc.com

 
Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.aphriainc.com
  • PO Box 20009 269 Erie St South
    Leamington, ON CAN N8H 3C4
  • Phone: 844.427.4742

Executives

Name Title Contact Details
Maureen Berry
Vice President of Corporate Human Resources Profile

Similar Companies

U.S MAX HEALING PRODUCTS,INC

U.S MAX HEALING PRODUCTS,INC is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadila Pharmaceuticals

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world.

Monticello Drug Companies

Monticello Drug Companies is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Attenua

Attenua, Inc. is a pharmaceutical company developing antitussive medications.